ESE Releases Landmark Menopause Guidelines Covering Hormones, POI and Cancer Risk
The European Society of Endocrinology issues comprehensive 2025 clinical guidelines for managing menopause, perimenopause, and premature ovarian insufficiency.
Summary
The European Society of Endocrinology (ESE) has published a major 2025 clinical practice guideline addressing the evaluation and management of menopause and perimenopause. With postmenopausal women representing a rapidly growing global population, and roughly 25% suffering debilitating symptoms, the guideline aims to equip all healthcare professionals with evidence-based tools. It covers natural menopause, premature ovarian insufficiency (POI), early menopause, and special cases where hormone therapy may be inappropriate — including women with or at high risk of breast cancer. The document weighs benefits and risks of hormone therapy, summarizes non-hormonal alternatives, and tackles the contested role of menopausal hormone therapy in chronic disease prevention.
Detailed Summary
Menopause is a universal biological transition affecting the 51% of the global population that is female, yet clinical management remains inconsistent and often inadequate. As the number of postmenopausal women worldwide continues to grow, and with approximately one in four experiencing symptoms severe enough to impair daily life, standardized, evidence-based guidance has never been more necessary.
The European Society of Endocrinology convened an international panel of experts — spanning gynecology, endocrinology, reproductive medicine, and clinical epidemiology — to develop this 2025 Clinical Practice Guideline. Published in the European Journal of Endocrinology, it spans 33 pages and addresses the full spectrum of menopausal experiences, from typical midlife menopause to premature ovarian insufficiency (POI) occurring before age 40 and early menopause before age 45.
A central focus is hormone therapy (HT): the guideline carefully outlines the benefits — relief of vasomotor symptoms, genitourinary syndrome, mood disturbance, and sleep disruption — against the risks, including breast cancer and cardiovascular considerations. It also provides a framework for women for whom hormones are contraindicated, such as those with current or prior hormone-sensitive breast cancer, summarizing evidence for non-hormonal pharmacological and non-pharmacological alternatives.
The guideline also tackles the highly debated question of whether menopausal hormone therapy can prevent chronic diseases such as osteoporosis, cardiovascular disease, or cognitive decline. This remains an area of active research with nuanced, population-specific evidence.
For clinicians, the practical value lies in having a single authoritative European reference that addresses diverse patient profiles. Caveats include the guideline's reliance on existing literature, which itself contains study heterogeneity, and the reality that individual risk-benefit calculations remain complex and patient-specific.
Key Findings
- About 25% of postmenopausal women experience debilitating symptoms warranting clinical intervention.
- Guideline covers natural menopause, POI, early menopause, and hormone-contraindicated cases including breast cancer.
- Hormone therapy benefits and risks are systematically evaluated, with non-hormonal alternatives also summarized.
- The role of HT in chronic disease prevention — cardiovascular, bone, cognitive — is addressed but remains contested.
- Developed by an international ESE expert panel to standardize care across all healthcare settings in Europe.
Methodology
This is a clinical practice guideline developed by the European Society of Endocrinology through a multinational expert panel. It is based on systematic review of existing evidence rather than original primary research. Recommendations are graded according to evidence quality and clinical consensus.
Study Limitations
As a guideline based on existing literature, it inherits the limitations of the underlying studies, including heterogeneous trial populations and varying hormone formulations. Individual patient risk-benefit assessments remain complex and must account for personal history, preferences, and comorbidities.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: